Wu 2011b.

Methods	Study design: Randomised clinical trial Study duration: Not reported Duration of follow‐up: 3 years Setting: Hospital
Participants	Age (mean ± SD): 50.6 ± 12.3 years Male (n/total): 76/90 Tumour diameter > 3 cm
Interventions	TACE + cryoablation group (n = 45): TACE: Chemotherapeutic drugs: 5‐fluorouracil 0.5‐1 g and epirubicin 10‐40 mg Cryoablation: The interval between TACE and RFA was 1 week. TACE group (n = 45): Chemotherapeutic drugs: 5‐fluorouracil 0.5‐1 g and epirubicin 10‐40 mg
Outcomes	Serum level of AFP Tumour diameter 1‐, 2‐, and 3‐year survival rates
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.